Evaxion Biotech AS (EVAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evaxion Biotech AS (EVAX) has a cash flow conversion efficiency ratio of 0.424x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.01 Million) by net assets ($-4.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evaxion Biotech AS - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Evaxion Biotech AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Evaxion Biotech AS carry for a breakdown of total debt and financial obligations.
Evaxion Biotech AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evaxion Biotech AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Senetas Corporation Ltd
AU:SEN
|
-0.024x |
|
Imugene Ltd
AU:IMU
|
-0.620x |
|
Synergetic Auto Performance Public Company Limited
BK:ASAP
|
1.134x |
|
Birman Wood and Hardware Ltd
TA:BIRM
|
-0.107x |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
-0.318x |
|
Hitron Systems
KO:019490
|
-0.277x |
|
Nova Wellness Group Bhd
KLSE:0201
|
0.051x |
|
MegaMD Co. Ltd
KQ:133750
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Evaxion Biotech AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Evaxion Biotech AS from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see EVAX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.65 Million | $-12.94 Million | 7.833x | +109.38% |
| 2023-12-31 | $-4.73 Million | $-17.69 Million | 3.741x | +220.51% |
| 2022-12-31 | $8.30 Million | $-25.77 Million | -3.104x | -359.08% |
| 2021-12-31 | $32.44 Million | $-21.93 Million | -0.676x | +61.74% |
| 2020-12-31 | $7.04 Million | $-12.44 Million | -1.767x | -135.48% |
| 2019-12-31 | $9.36 Million | $-7.03 Million | -0.750x | -135.09% |
| 2018-12-31 | $-931.00K | $-1.99 Million | 2.139x | -- |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected mel… Read more